| I–II | III–IV |
---|---|---|
Age | ||
 ≤ 65 | 0 (0.0%) | 1 (12.5%) |
 > 65 | 4 (50.0%) | 3 (37.5%) |
Type | ||
 Adenocarcinoma | 4 (50.0%) | 4 (50.0%) |
Sex | ||
 Male | 1 (12.5%) | 3 (37.5%) |
 Female | 3 (37.5%) | 1 (12.5%) |
T-stage | ||
 T1 | 1 (12.5%) | 0 (0.0%) |
 T2 | 0 (0.0%) | 0 (0.0%) |
 T3 | 2 (25.0%) | 1 (12.5%) |
 T4 | 1 (12.5%) | 3 (37.5%) |
N-stage | ||
 N0 | 4 (50.0%) | 0 (0.0%) |
 N1 | 0 (0.0%) | 4 (50.0%) |
 N2 | 0 (0.0%) | 0 (0.0%) |
M-stage | ||
 M0 | 4 (50.0%) | 1 (12.5%) |
 M1 | 0 (0.0%) | 3 (37.5%) |
Location | ||
 Ascending colon | 2 (25.0%) | 1 (12.5%) |
 Sigmoid colon | 1 (12.5%) | 3 (37.5%) |
 Appendix colon | 1 (12.5%) | 0 (0.0%) |
Chemotherapy | ||
 Yes | 0 (0.0%) | 0 (0.0%) |
 No | 4 (50.0%) | 4 (50.0%) |